BioCentury | Jan 17, 2018
Distillery Therapeutics

Cancer

...IFNB1 and human serum albumin (HSA) fusion protein, in Phase I testing to treat MS. Bolder BioTechnology Inc....
BioCentury | Sep 3, 2007
Company News

Bolder BioTechnology, National Institutes of Health autoimmune news

...of rheumatoid arthritis (RA). The protein also is in early preclinical development to treat cancer. Bolder BioTechnology Inc....
BioCentury | Jan 17, 2005
Company News

Bolder BioTechnology other research news

...pharmacology studies of erythropoiesis-stimulating protein to treat anemia associated with chronic kidney disease and chemotherapy. Bolder BioTechnology Inc....
BioCentury | Jan 17, 2005
Company News

Bolder BioTechnology other research news

...as a potential treatment for growth hormone deficiency, short stature in children and HIV-associated wasting. Bolder BioTechnology Inc....
Items per page:
1 - 4 of 4
BioCentury | Jan 17, 2018
Distillery Therapeutics

Cancer

...IFNB1 and human serum albumin (HSA) fusion protein, in Phase I testing to treat MS. Bolder BioTechnology Inc....
BioCentury | Sep 3, 2007
Company News

Bolder BioTechnology, National Institutes of Health autoimmune news

...of rheumatoid arthritis (RA). The protein also is in early preclinical development to treat cancer. Bolder BioTechnology Inc....
BioCentury | Jan 17, 2005
Company News

Bolder BioTechnology other research news

...pharmacology studies of erythropoiesis-stimulating protein to treat anemia associated with chronic kidney disease and chemotherapy. Bolder BioTechnology Inc....
BioCentury | Jan 17, 2005
Company News

Bolder BioTechnology other research news

...as a potential treatment for growth hormone deficiency, short stature in children and HIV-associated wasting. Bolder BioTechnology Inc....
Items per page:
1 - 4 of 4